x
Filter:
Filters applied
- Coronavirus (COVID-19) Collection
- Coronavirus disease 2019Remove Coronavirus disease 2019 filter
- Angiotensin-converting enzyme IIRemove Angiotensin-converting enzyme II filter
Publication Date
Please choose a date range between 2021 and 2021.
Coronavirus (COVID-19) Collection
1 Results
- Research ArticleOpen Access
Inverse association between hypertension treatment and COVID-19 prevalence in Japan
International Journal of Infectious DiseasesVol. 108p517–521Published online: June 2, 2021- Masako Kinoshita
- Kazuaki Sato
- Balachandar Vellingiri
- Shawn J. Green
- Masami Tanaka
Cited in Scopus: 2SARS-CoV-2 is the causative virus for COVID-19. Cell entry of SARS-CoV-2 depends on angiotensin-converting enzyme II (ACE2), which is a membrane-associated zinc peptidase, and transmembrane serine protease 2, which is a cellular serine protease (Zhou et al., 2020b; Hoffmann et al., 2020; Hirano and Murakami, 2020). ACE2 is homologous with, but acts antagonistically to, angiotensin-converting enzyme (ACE) and has the critical function of protecting the lungs from severe acute injury (Imai et al., 2005).